المؤلفون: D. I. Sadykova, D. R. Sabirova, N. V. Kustova, N. N. Firsova, G. A. Khusnullina

المصدر: Rossijskij Vestnik Perinatologii i Pediatrii, Vol 63, Iss 5, Pp 167-171 (2018)

مصطلحات موضوعية: дети, легочная артериальная гипертензия, врожденный порок сердца, диагностика, лечение, силденафил, Pediatrics, RJ1-570

Relation: https://www.ped-perinatology.ru/jour/article/view/744; https://doaj.org/toc/1027-4065; https://doaj.org/toc/2500-2228; https://doaj.org/article/d491a2a178ac465499e292e8d2847e00

الاتاحة: https://doi.org/10.21508/1027-4065-2018-63-5-167-171
https://doaj.org/article/d491a2a178ac465499e292e8d2847e00

المؤلفون: D. I. Sadykova, D. R. Sabirova, A. R. Shakirova, N. N. Firsova, G. A. Khusnullina, N. V. Kustova, Д. И. Садыкова, Д. Р. Сабирова, А. Р. Шакирова, Н. Н. Фирсова, Г. А. Хуснуллина, Н. В. Кустова

المصدر: Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics); Том 61, № 5 (2016); 149-154 ; Российский вестник перинатологии и педиатрии; Том 61, № 5 (2016); 149-154 ; 2500-2228 ; 1027-4065 ; 10.21508/1027-4065-2016-61-5

مصطلحات موضوعية: ингибиторы фосфодиэстеразы-5, pulmonary arterial hypertension, portopulmonary hypertension, endothelin receptor antagonists, phosphodiesterase 5 inhibitors, легочная артериальная гипертензия, портопульмональная гипертензия, антагонисты эндотелиновых рецепторов

وصف الملف: application/pdf

Relation: https://www.ped-perinatology.ru/jour/article/view/398/423; Galiè N., Humbert M., Vachiery J.L. et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J 2015; 46: 4: 903–975.; Galie N., Hoeper M.M., Humbert M. et al. Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology and the European Respiratory Society, endorsed by the International Society of Heart and Lung Transplantation. Eur Heart J 2009; 30: 20: 2493–2537.; Simonneau G., Gatzoulis M.A., Adatia I. et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013; 62: D34 — D41.; Руководство по легочной гипертензии у детей. Под ред. Л.A. Бокерия, С.В. Горбачевского, М.А. Школьниковой. М 2013; 416. 416 (Guidelines for pulmonary hypertension in children. L.A. Bokeriya, S.V. Gorbachevskij, M.А. Shkol’nikova (eds). Moscow 2013; 416. (in Russ)); Krowka M.J., Miller D.P., Barst R.J. et al. Portopulmonary hypertension: a report from the US-based REVEAL Registry. Chest 2012; 141: 906–915.; Humbert M., Sitbon O., Chaouat A. et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006; 173: 1023–1030.; Herve P., Lebrec D., Brenot F. et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998; 11: 1153–1166.; Hoeper M.M., Krowka M.J., Strassburg C.P. Portopulmonary hypertension and hepatopulmonary syndrome. Lancet 2004; 363: 1461–1468.; Colle I.O., Moreau R., Godinho E. et al. Diagnosis of portopulmonary hypertension in candidates for liver transplantation: a prospective study. Hepatology 2003; 37: 401–409.; Kochar R., Nevah R., Rubin M.I. et al. Pulmonary complications of cirrhosis. Curr Gastroenterol Rep 2011; 13: 34–39.; Swanson K.L., Wiesner R.H., Nyberg S.L. et al. Survival in portopulmonary hypertension: Mayo Clinic experience categorized by treatment subgroups. Am J Transplant 2008; 8: 2445–2453.; Гурьянов В.А., Толмачев Г.Н. Первичная (идиопатическая) легочная гипертензия (синдром Арриллага — Аэрза) и беременность — интенсивная терапия и анестезия. Анестезиол и реаниматол 2014; 6: 56–58. (Gur’yanov V.А., Tolmachev G.N. Primary (idiopathic) pulmonary hypertension (Arrillaga — Aerza syndrome) and pregnancy — intensive care and anesthesia. Anesteziol reanimatol 2014; 6: 56–58. (in Russ)); Roberts K.E., Fallon M.B., Krowka M.J. et al. Genetic risk factors for portopulmonary hypertension in patients with advanced liver disease. Am J Respir Crit Care Med 2009; 179: 835–842.; Golbin J.M., Krowka M.J. Portopulmonary hypertension. Ann Thorac Med 2010; 5: 1: 5–9.; Krowka M.J., Swanson K.L., Frantz R.P. et al. Portopulmonary hypertension: results from a 10-year screening algorithm. Hepatology 2006; 44: 1502–1510.; Kawut S.M., Krowka M.J., Trotter J.F. et al. Clinical risk factors for portopulmonary hypertension. Hepatology 2008; 48: 196–203.; Le Pavec J., Souza R., Herve P. et al. Portopulmonary hypertension: survival and prognostic factors. Am J Respir Crit Care Med 2008; 178: 637–643.; Halank M., Knudsen L., Seyfarth H.J. et al. Ambrisentan improves exercise capacity and symptoms in patients with portopulmonary hypertension. Z Gastroenterol 2011; 49: 1258– 1262.; Porres-Aguilar M., Zuckerman M.J., Figueroa-Casas J.B. et al. Portopulmonary hypertension: state of the art. Ann Hepatol 2008; 49: 1258–1262.; Cohn J.N. Optimal diuretic therapy for heart failure. Am J Med 2001; 111: 7: 577.; Galie N., Olschewski H., Oudiz R.J. et al. Ambrisentan for the treatment of pulmonary arterial hypertension. Results of the amrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (APIES) study 1 and 2. Circulation 2008; 117: 3010– 3019.; Galie N., Rubin U., Hoeper M. et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomized controlled trial. Lancet 2008; 371: 2093–2100.; Inohara T., Niwa K., Yao A. Survey of the current status and management of Eisenmenger syndrome: A Japanese nationwide survey. J Cardiol 2014;63: 286–290.; Beghetti M. Bosentan in pediatric patients with pulmonary arterial hypertension. Curr Vasc Pharmacol 2009; 7: 225–233.; Beghetti M., Haworth S.G., Bonnet D. et al. Pharmacokinetic and clinical profile of a novel formulation of bosentan in children with pulmonary arterial hypertension: the FUTURE-1 study. Br J Clin Pharmacol 2009; 68: 948–955.; Чазова И.Е., Черняская А.М., Мартынюк Т.В. и др. Актуальные вопросы хронической тромбоэмболической легочной гипертензии: мнения экспертов. Кардиол вестн 2015; 1: 78–79. (Chazova I.E., Chernyaskaya А.M., Martynyuk T.V. et al. Topical issues of chronic thromboembolic pulmonary hypertension: expert opinions. Kardiol vestn 2015; 1: 78–79. (in Russ)); https://www.ped-perinatology.ru/jour/article/view/398

الاتاحة: https://www.ped-perinatology.ru/jour/article/view/398
https://doi.org/10.21508/1027-4065-2016-61-5-149-154

المؤلفون: S. A. Fufaev, I. V. Timofeeva, G. R. Khusnullina, S. L. Surgutskaya

المصدر: Oil and Gas Studies. :37-43

مصطلحات موضوعية: Mineralogy, Layer (electronics), Geology, Geological structure

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::4c4bdc5d96a4fbf3bd1723161c6b45be
https://doi.org/10.31660/0445-0108-2016-5-37-43

المؤلفون: G. M. Khusnullina, N. A. Buina, I. A. Nuretdinov

المصدر: ChemInform. 22

مصطلحات موضوعية: Chemistry, Organic chemistry, General Medicine, S derivatives, Combinatorial chemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::55761ec63f01420195e10acac6f96095
https://doi.org/10.1002/chin.199106207

المؤلفون: N. A. Buina, G. M. Khusnullina, I. A. Nuretdinov

المصدر: Bulletin of the Academy of Sciences of the USSR Division of Chemical Science. 39:1022-1024

مصطلحات موضوعية: chemistry.chemical_compound, Chemistry, Amide, Organic chemistry, General Chemistry

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::a12a33bd21b6138c1dd7519129da1015
https://doi.org/10.1007/bf00961706